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ABSTRACT
The cannabinoid system is important for maintaining neuron-to-neuron
communication within the mammalian brain. One of the most commonly used
substances to alter the cannabinoid system is cannabis. Individuals who are
exposed to cannabis report having dissociable effects; both positive and negative.
High amounts of THC have been commonly associated with the negative effects
of cannabis, whereas CBD can be used to counter these. Pre-clinical evidence
suggests that the combination of the two compounds can produce a therapeutic
benefit for individuals who are susceptible to the effects of THC. The present study
investigates

whether

the

combination

of

THC+CBD

can

prevent

electrophysiological changes induced by THC. Using In Vivo electrophysiology,
simultaneous recordings of single unit activity both in the ventral hippocampal and
prefrontal cortex were compared after infusions of cannabinoids into the
basolateral amygdala. THC induced changes in the PFC to increase overall activity
whereas the combined dose of THC+CBD returned cortical activity to baseline and
introduced a potential benefit in reduced hippocampal activity.

KEYWORDS: Basolateral Amygdala, Cannabidiol, Cannabis, Delta-9
Tetrahydrocannabinol, CB1R, Electrophysiology, Endocannabinoid, Local Field
Potential, Prefrontal Cortex, Psychosis, Schizophrenia, Ventral Hippocampus,
5HT-1A.
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1.1 Introduction
Endocannabinoid signalling in the mammalian brain is important for
regulating the coordination of communication between brain regions to produce
everyday behaviours. A common drug of abuse linked to alterations in this
signalling pathway is Cannabis (i.e., Cannabis Sativa). It is well known that
individuals can experience both positive and negative affective experiences
following cannabis exposure. To study these effects, researchers have focused on
two main compounds located in the plant: Delta-9-Tetrahydrocannabinol (THC)
and Cannabidiol (CBD). The mind-altering (i.e. psychotropic) effects of cannabis
are associated with THC, whereas CBD can treat psychosis symptoms (i.e.
antipsychotic) (D’Souza et al., 2004; Mechoulam et al., 1988; Pertwee, 2004;
Russo & Guy, 2006; Zuardi et al., 1982; Zuardi et al. 1991). A growing body of
literature is now investigating how the combination of the two can prevent
disturbances in behavioural and cognitive functioning through its effects on the
endocannabinoid system.
Previous studies have examined the potential therapeutic benefits of
combined THC+CBD formulations on mental health-related behaviours using
systemic administration routes (Boggs et al., 2017, Jacobs et al., 2016; Wright et
al., 2013). As of yet, no clear demonstration of the combined and/or synergistic
effects of THC and CBD has been investigated with respect to specific regions in
the brain. As the amygdala region is involved in general endocannabinoid
transmission and has previously produced different effects between THC and CBD
in the human brain, we chose this as the primary region of interest in this study
(Bhattacharyya et al., 2010; Bhattacharyya et al., 2017; Tan et al., 2010; Tan et
al., 2011;). Furthermore, the amygdala is interconnected with both cortical and
hippocampal regions that are impacted by THC in cognition, anxiety, memory
(Englund et al., 2013; Lichtman et al., 1995; Jentsch et al., 1997; Rubino et al.,
2008). The work presented in this thesis is the first attempt to characterize the
effects of THC and CBD in the amygdala of rodents using in vivo
electrophysiological recordings. Understanding how these compounds impact

2

distant circuits provides insights in how they act on the brain to produce a potential
therapeutic benefit when combined.
1.1.1 The Effects of Cannabis on Mental Health
Cannabis is currently the most commonly used illicit drug in the world. In
2015 in Canada alone, approximately 3.6 million people report using cannabis and
usage is expected to increase by the end of the decade (Rotermann & Macdonald,
2018). The passing of medical marijuana laws in select states in the United States
of America (USA) have so far seen additional rises in illicit cannabis use (Hasin et
al., 2017). Among teenagers, legalization of medical marijuana has led to a
decrease in perceived risk and an increased interest to recreationally use (Miech
et al., 2015). As compounds associated with cannabis become more commercially
available, with the continued legalization of marijuana in US states, and with
upcoming legalization in Canada in 2018, more attention is being paid to the
potential positive and negative health effects of cannabis use.

Although symptom duration and intensity vary depending on what age one
begins recreational cannabis use, users claim to experience acute positive benefits
such as reduced nausea, increased relaxation, and a positive high (Mechoulam &
Parker, 2012). In contrast, some negative effects that may occur are impairments
in attention and memory, increased anxiety, and negative highs associated with
psychotomimetic effects (D’Souza et al.,2004; D’Souza et al., 2005; Rottanburg et
al., 1982; Volkow et al., 2016). These symptoms differ in duration from short-term
to long-term; cannabis, like any drug, has the potential to alleviate or add negative
effects. Considerable evidence now links cannabis use with alterations to the
endocannabinoid system in the mammalian brain, causing emotional and cognitive
dysregulation associated with various neuropsychiatric disorders (Laviolette &
Grace, 2006; Parsons & Hurd, 2015; Volkow et al., 2016; Zehra et al., 2018). For
example, exposure to cannabis in teenagers is associated with a greater risk for
developing psychosis in adulthood (Arseneault et al., 2002; Arseneault, Cannon,
Witton, & Murray, 2004; Stefanis et al., 2004). Evidence for these risks are also
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supported in animal research. In preclinical models, adolescent exposure to
chronic THC causes deficits in cognitive task performance associated with
schizophrenia and psychosis (Renard et al., 2017a; Renard et al., 2017b). These
deficits are further supported with changes in cortical and sub-cortical molecular
signalling pathways found in animal models of schizophrenia (mTOR, GAD 67, &
GSK). In addition, there is a growing concern about the epidemiological impact of
increased THC content in cannabis products in the past few decades (Cascini,
Aiello, Di Tanna, 2012). Increased ratios of THC coupled with the known
vulnerability of adolescent populations can potentially lead to an increase in
diagnosis rates of psychosis and schizophrenia. Cannabis use does not in itself
cause these disorders, yet a growing body of literature finds that individuals with
genetic (polymorphisms of COMT and AKT1) and environmental (childhood abuse
and familial relatives with these disorders) risks for these disorders may have
exaggerated symptom onset, duration, or intensity when chronically exposed to
cannabis (Arendt et al., 2008; Caspi et al., 2005; Forti et al., 2012; Henquet et al.,
2009; Houston et al., 2008; Radhakrishnan et al., 2014).

Central to understanding the pharmacological and psychotropic effects of
cannabis is identifying the compounds responsible. Of over 100 phytochemicals
contained in the plant, THC and CBD have been the most widely studied in terms
of effects on mental health. Psychotropic effects associated with the plant have
been linked to THC (D’Souza et al., 2004; Pertwee, 2004; Mechoulam & Parker,
2012). Opposite to THC, CBD does not produce any mood alterations or highs on
its own, yet it has been associated with antipsychotic and antianxiety-like benefits
(Russo & Guy, 2006; Zuardi et al., 1982; Zuardi et al. 1991). Both compounds
interact with the endocannabinoid system differently to alter the mammalian brain
and produce behavioural effects (Atakan, 2012; Morales, Hurst, & Reggio, 2017;
Pertwee, 2008;). The dissociation in the effects of cannabis may be due to the way
the endocannabinoid system regulates the brain when the additive effects of these
compounds interact when combined.
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1.1.2 Endocannabinoid System

The endocannabinoid system is important for proper development and
functioning of the mammalian brain (Meyer, Lee, & Gee, 2018). This system
contains endogenous ligands and receptors that are synthesized and expressed
throughout the entire brain, allowing proper cell-to-cell communication between
synapses and regulation of brain area coordination (Laviolette & Grace, 2006;
Parsons & Hurd, 2015). Both arachidonoylglycerol (2-AG) and anandamide (AEA)
are the most well studied endogenous ligands that act on the endocannabinoid
system (Devane et al., 1992; Mechoulam et al., 1996). Both ligands act as
retrograde messengers that are synthesized and released from the postsynaptic
cell to be released into the synapse. From there, they travel to bind and activate
cannabinoid 1 receptors (CB1R) located on presynaptic terminals. CB1Rs are one
of the most abundant receptors found throughout the mammalian brain (Atakan,
2012; Morales, Hurst, & Reggio, 2017). These receptors are classified as Gprotein-coupled receptors with a seven transmembrane domain. The activation of
these receptors by these ligands blocks adenyl cyclase and downstream targets
to prevent the release of neurotransmitter vesicles (Howlett et al., 1986). Overall,
as

cells

communicate

to

generate

postsynaptic

action

potentials,

the

endocannabinoid system responds by releasing 2-AG and AEA to bind to CB1R
to cause an overall inhibition on the presynaptic cell and therefore prevents any
dysregulation that could be caused by over excitation in the synapse (Hoffman &
Lupica, 2000; Kano et al., 2009; Sullivan 1999; Wilson & Nicoll, 2001). In addition
to endogenous ligands, synthesized endocannabinoids like THC can bind to CB1R
to alter overall brain function.
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1.1.3 Properties and Mechanisms of Delta-9 Tetrahydrocannabinol in the
Brain

The primary phytochemical responsible for the psychoactive effects of
cannabis has been linked to THC and to changes in CB1R functioning. In
particular, THC acts as a partial agonist for the CB1R.Because of this, THC can
lead to different agonist-antagonist effects depending on the number of receptors
currently expressed, the cell type, and the current presence of other endogenous
ligands for the CB1R (Morales et al., 2017). Despite this, THC will tend to interact
with the CB1R like the endocannabinoids AEA, where the net result on the
synapse is to reduce the overall exogenous release of neurotransmitter vesicles
from presynaptic terminals (Laaris, Good, & Lupica, 2010; Shen & Thayer, 1998).

As most CB1Rs are located on glutamatergic and gamma aminobutyric acid
(GABA) expressing cells, THC will either reduce inhibition or increase disinhibition
depending on where it is expressed (Morales et al., 2017). This will determine how
the cannabinoid impacts brain functioning. For instance, rodents exposed to THC
will have increased extracellular dopamine and glutamate and decreased GABA
neurotransmitter levels measured in the PFC (Pistis et al., 2002). Glutamatergic
release in the hippocampus is impaired but can be reversed with the presence of
CB1 antagonists (Fan et al., 2010). THC can also increase striatal dopamine
release, similar to other drugs of abuse, via CB1R and therefore lead to emotional
salience misattributions and distortion (Wijayendran et al., 2016). In addition, THC
administered to prenatal fetuses or during adolescence results in abnormal
development of glutamatergic and dopaminergic signalling in the rodent brain to
impact cognition and attention (Castaldo et al., 2007; Renard et al., 2016, Renard
et al., 2017a; Renard et al., 2017b).

The interaction of these various neurotransmitter systems during exposure to
THC can alter cognitive and behavioural functioning in the mammalian brain. For
example, in rodents, THC can cause greater errors in working memory
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performance, which is reversed with a CB1 antagonist (Lichtman & Martin, 1996).
In both young and adult rodents, systemic THC produces an anxiogenic effect as
measured in the elevated plus maze, light-dark, and open field locomotion tasks
(Sapyta et al., 2007). In humans, a single administration of intravenous THC can
cause healthy individuals to feel increased anxiety, verbal working memory
impairments, positive, negative, cognitive and psychosis-like symptoms, along
with feelings of a high (D’Souza et al., 2005). Furthermore, individuals with a
history of psychotic symptoms experience similar deficits after acute THC
administration (D’Souza et al, 2006). Chronic exposure to THC during critical
neurodevelopmental periods is associated with schizophrenia-like deficits in
adulthood, coupled with a loss in cortical interneurons and modulation of the
mesolimbic system (Renard et al, 2017a; Renard et al., 2017b).

Cortical overexcitation via loss of inhibitory interneuron regulation may result in
dysregulated GAMMA oscillatory activity, a neuropathological feature associated
with schizophrenia (Lee et al., 2010; Symond et al. 2005). Furthermore,
administration of THC can alter GAMMA oscillations in both the prefrontal cortex
and the hippocampus, two regions that are involved with schizophrenia (Renard et
al., 2017a; Renard et al., 2017b; Robbe et al., 2006;). Studying how THC alters
the endocannabinoid system is therefore important to understanding how maladaptive effects can arise from use in healthy and clinical populations.

1.1.4 Properties and Mechanisms of Cannabidiol in the Brain

In contrast to THC, CBD has very low affinity as a CB1 receptor antagonist
(Thomas et al., 2009), leading researchers to search for alternative sites of action
to explain its effects. CBD can act as a partial agonist to the 5HT-1A serotonin
receptor (Pertwee, 2004; Russo et al., 2005), a weak partial agonist for D2
receptors (Seeman et al., 2016), a weak negative allosteric modulator to Mu opioid
receptors (Kathmann et al., 2006) and activates the GPR55 receptor (Ryberg et
al., 2007). Recently, researchers have focused on CBD’s involvement with the
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5HT-1A receptor to regulate cell-to-cell communication. In general, activation of
the 5HT-1A autoreceptors located on post synaptic somato-dendritic sites causes
inhibition of that cell’s firing output (Polter & Li, 2010; Tada et al., 2004;). Following
this cell firing inhibition, CBD administration could potentially inhibit post-synaptic
transmission and therefore impact the activity of projected areas. For instance,
intracranial infusion of CBD in the shell of the nucleus accumbens (NASh) can
attenuate ventral tegmental area (VTA) dopamine neuron firing (Norris et al., 2016;
Renard et al., 2016).

Similar to THC, the effects of CBD are determined by the location of its
target receptors, with activation in different brain regions potentially causing
different behavioural effects. Although CBD does not show any psychotropic
effects, research has linked its potential in having anxiolytic, anti-inflammatory, and
anti-psychotic-like properties (Russo & Guy, 2006; Zuardi et al., 1982; Zuardi et al.
1991). Anxiolytic effects of CBD have been associated with behavioural changes
in forced swim tasks (Sartim et al., 2016), elevated plus maze tasks (Campos and
Guimares, 2008), facilitating fear extinction (Bittencourt et al., 2008; Do Monte et
al., 2013), and impairing fear-associated memories (Gomes et al., 2010, Norris et
al., 2016, Stern et al., 2017). CBD has also shown antipsychotic-like benefits by
reducing sensory-motor gating deficits (Renard et al., 2016), preventing short-term
THC-induced memory and social interaction impairments (Malone et al., 2009;
Morgan et al., 2010), and dopamine-related psychomotor sensitization (Renard et
al., 2016). Although very few clinical trials exist in the literature, research
demonstrates that daily oral doses of CBD administered to schizophrenic
populations exhibit improvements in negative and cognitive symptoms comparable
to those treated with traditional antipsychotic medication (Leweke et al., 2012). The
normal circulation of endocannabinoid levels can also interact with CBD. Acute
administration of CBD increases overall AEA levels by blocking reuptake and fatty
acid amide hydrolase inhibition (Bisogno et al., 2001; Ligresti et al., 2006). This
effect on increased release of AEA in the synapse would reduce the overall release
of neurotransmitter vesicles from presynaptic terminals, and therefore inhibit cell-
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to-cell communication (Hoffman & Lupica, 2000; Kano et al., 2009; Sullivan 1999;
Wilson & Nicoll, 2001). Due to its interactions with the endocannabinoid system
and the independent benefits that it might have on behaviour, CBD appears to
have therapeutic potential for users.

1.1.5 Therapeutic potential of combined THC and CBD formulations
Although the mechanisms underlying CBD’s ability to interact with the
endocannabinoid system are still being characterized, growing evidence suggests
that it may be used to counter some of the negative side effects of THC use. In
non-human primates, THC+CBD ratios of 1:1 and 1:3 can reverse temporary THCinduced cognitive and visuospatial attention impairments (Jacobs et al., 2016;
Wright et al., 2013). Pre-treatment at a systemic 1:20 ratio can prevent the social
interaction deficits associated with THC (Malone et al., 2009). Furthermore, THCinduced conditioned place aversion can be blocked at a 1:1 combined CBD ratio,
despite it having no preference effects by itself (Vann et al., 2008).
In human studies, the dose used to demonstrate CBD’s potential restorative
effects is much higher. For example, individuals given 10mg of THC display
increases in skin conductance responses and subjective anxiety ratings to fear
stimuli whereas CBD alone (at 600mg) does not elicit any change compared to
placebo (Fusar-Poli et al., 2009). In recreational users, those who smoked
cannabis with higher CBD to THC concentrations did not display impairments on
memory in contrast with those who had lower concentrations of CBD and did have
memory issues (Morgan et al., 2010). In healthy participants, THC IV infusions
cause deficits in hippocampus-dependent episodic memory performance but pretreatment with 600mg CBD improved performance to placebo levels (Englund et
al., 2013). In addition, a 1:2 oral dose combination prevented THC-induced
impairments in emotional facial recognition (Hinodocha et al., 2015). Although
more studies are needed, considerable evidence suggests that CBD may prevent
some of the neuropsychiatric effects seen with THC, yet not in all situations. In
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some situations, CBD can induce an effect independent of the presence of THC,
for instance CBD is able to block fear memory reconsolidation with or without THC
(Stern et al., 2012; Stern et al., 2015). This could suggest that CBD can prevent
THC deficits in some cases and act on the brain independently of THC in other
cases. Furthermore, some ratios of THC:CBD may even allow a user to experience
a higher dose of THC while avoiding some of the negative side-effects (Boggs et
al., 2017). Overall, CBD’s potential to prevent or reverse the effects of THC when
combined may depend on the dose ratio and the animal species researched.

1.2 Cannabinoid modulation of the basolateral amygdala, ventral
hippocampus, and prefrontal cortex
The endocannabinoid system is involved with multiple brain regions that are
important for regulating cognition, emotion, memory, and anxiety (Laviolette &
Grace, 2006; Mechoulam & Parker, 2012). The interference of these processes
from cannabis may be a result of how THC and CBD potentially interact within
these regions. For example, in chronic cannabis users, CB1Rs are downregulated
in areas such as the hippocampus and PFC, which are important for cognition and
memory (Hirvonen et al., 2011). Structural neuroimaging and resting state studies
have also shown reductions in hippocampal, prefrontal cortex, and amygdala brain
volume and activity in chronic cannabis users (Block et al., 2000; Yucel et al.,
2008). Furthermore, acute administration of CBD has been shown to decrease
blood oxygenated levels in both the amygdala and hippocampus (De Crippa et al.,
2004). All three regions are comprised of the mesolimbic system, which has been
implicated in reward, learning, anxiety, and cognition (Laviolette, 2017). It is
therefore important to understand how these regions are influenced by
phytocannabinoid exposure to determine how THC and CBD may produce their
differential effects on the brain and neuropsychiatric phenomena.
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1.2.1 Cannabinoid Effects on the Basolateral Amygdala

Anatomically, the amygdala is clustered into functionally distinct regions.
The Basolateral Amygdala (BLA) is one area considered important for emotion and
anxiety regulation (Janak & Tye, 2015). The BLA has cortical-like features, as it is
compromised of two main cell types: glutamatergic pyramidal projection neurons
and GABAergic local interneurons (Ramikie et al., 2012). The CB1R is highly
expressed in the BLA, with mRNA studies revealing that approximately 95% of
cells co-express GABAergic markers (Marsicano & Lutz, 1999). This suggests its
predominant expression is on BLA interneuron terminals. Given the location of
these receptors, activation via cannabinoid transmission decreases spontaneous
and evoked transmission on the BLA pyramidal neurons (Katona et al., 2001).
Therefore, activation of these CB1Rs is predicted to indirectly increase pyramidal
neuron firing by decreasing GABA interneuron inhibition, therefore causing an
increase in activity to downstream targets of the BLA (Ramikie et al., 2012).

Efferent projections from the BLA go to multiple neural regions, but of most
importance to this study are those going to the hippocampus and PFC (Knapska
et al., 2007; Sah et al., 2003). For example, cannabinoid-mediated modulation of
these specific pathways can alter anxiety and emotional memory processing
(Felix-Ortiz et al., 2014; Laviolette & Grace, 2006). In addition, being
interconnected with these regions positions the BLA as a central structure involved
in coordinating salient environmental stimuli and consolidating that information to
form emotional memories.

Considerable evidence demonstrates that cannabinoid transmission within
the BLA can affect emotion regulation and memory. Activation of intra-BLA CB1Rs
via an agonist will potentiate the acquisition of a fear memory, whereas a CB1R
antagonist has been shown to block the formation of emotional associative
memories (Tan et al., 2011). Endocannabinoid-mediated activation in the BLA also
causes animals to have increased anxiety and prevents the formation of aversive
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memories (Munguba et al., 2011). Micro-infusions of THC into the BLA alters
memory and causes an anxiogenic effect on elevated plus maze and locomotion
tasks (Rubino et al., 2008). Furthermore, activation of CB1R in the BLA can switch
morphine’s rewarding effects into aversive memory place preferences (Ahmad et
al., 2016). In humans, acute oral administration of THC in healthy subjects not only
increases anxiety and symptoms associated with psychosis but can cause an
increased blood oxygenated level in the amygdala when viewing negative stimuli
(Bhattacharyya et al., 2017). This effect was correlated with PET imaging
expression of CB1R in the amygdala, demonstrating the connection between the
effects of THC on emotional stimuli mediated through the cannabinoid receptor.
The same lab previously showed that an oral dose of CBD did not produce any
changes in the same behavioural measures relative to placebo, but found a
significant

decrease

in

amygdala

BOLD

signalling

compared

to

THC

administration (Bhattacharyya et al., 2010). These findings suggest that both CBD
and THC can have independent effects on amygdala activity to alter affective
processing and associated behaviours.

1.2.2 Effects of Cannabinoids in the Ventral Hippocampus
The hippocampus’ involvement in regulating emotion, stress, and learning
and memory processes makes it a potential target for the effects of cannabis use.
In particular, the ventral hippocampus is more involved with emotion and anxiety
phenomena as opposed to the dorsal region, which is important for spatial and
contextual memory processing (Fanselow & Dong, 2010). The ventral
hippocampus region in rodents is functionally analogous to the anterior
hippocampus in humans (Fanselow & Dong, 2010). Reductions of anterior
hippocampal volume occur in chronic cannabis users, with the most severe
reductions in individuals exposed to higher ratios of THC to CBD (Demirakca et
al., 2011).
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Within the ventral hippocampus, cannabinoid transmission is important in
regulating salience of environmental cues and in emotional memory formation.
Similar to the BLA, CB1R expression is mainly located on GABAergic interneurons
(Katona et al., 1999), which can cause an overexcitation towards the system via
interneuron inhibition when activated. Considerable evidence now suggests that
overexcitation of vHPC is responsible for behavioural deficits associated with
schizophrenia (Grace et al., 2010). For example, intracranial microinjections of a
CB1R agonist into the hippocampus impairs performance on radial arm maze
memory tasks similar to the effects seen with systemic THC (Lichtman et al., 1995).
Systemic THC and WIN55 (i.e., a full CB1R agonist) cause impairments in a
delayed nonmatch sample task which simultaneously co-occurs with alterations in
hippocampal cellular firing (Hampson & Deadwyler, 2000). A high dose of THC (5
ug) injected into the vHPC makes rodents more anxiolytic on the elevated plus
maze task (Rubino et al., 2008). Direct activation of the CB1R using WIN55 in the
vHPC can potentiate the acquisition of both reward and fear memories at nonrewarding or low foot shock conditions while also impairing social recognition
(Loureiro et al., 2015). This potentiation of non-salient cues is associated with
changes in the mesolimbic system with vHPC micro infusions of WIN55 increasing
activity in both NASh medium spiny and VTA dopamine neurons (Loureiro et al.,
2015; Loureiro et al., 2016). Furthermore, THC can also impact single unit and
local field potential (LFP) recordings in awake animals. Both systemic and
intracranial hippocampus injections of a CB1 full agonist decreases power for LFP
across Theta, Gamma, and Ripple events (Robbe et al., 2006). Although single
unit recordings were not analyzed, systemic injections of THC also decreased LFP
power in the same frequency bands (Robbe et al., 2006). Acute administration of
THC can reduce resting state ventral hippocampal activity, further implicating the
compound as a potential anti-psychotic to counter overexcitation of the circuit (De
Crippa et al., 2004).

Alterations from the vHPC can therefore impact other regions that are
interconnected. The vHPC shares unique neuronal connectivity between the PFC
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and the amygdala, unlike the dorsal hippocampus. Specifically, ventral
CA1/subiculum regions of the ventral hippocampus have re-occurring connections
with the posterior BLA and prelimbic regions of the PFC (Pitkanen et al., 2000;
Cenquizca & Swanson, 2007). This pathway, along with known properties of BLA
cannabinoid transmission, makes the ventral hippocampus an interesting target to
examine the local effects of THC and CBD administration in the context of
mesocorticolimbic circuitry.

1.2.3 Effects of Cannabinoids on the Prefrontal cortex

The prefrontal cortex is an important region to study the effects of
cannabinoid drugs on cognition, attention, and memory. In rodents, the pre-limbic
region of the PFC is interconnected with the BLA, potentially implicating this
pathway as important for endocannabinoid transmission (McGarry & Carter, 2017;
Tan et al., 2010; Tan et al., 2011). Similar to the BLA and vHPC, CB1R is highly
expressed within the PFC interneuron populations. Endocannabinoids, when
expressed in the pre-limbic regions of the PFC, can inhibit evoked excitatory
postsynaptic currents and therefore impact other interconnected regions
(Lafourcade et al., 2007). In addition, THC given systemically can also cause an
increase in mRNA expression in the PFC for c-fos, a marker for neuronal activation
(Egerton et al., 2001). In humans, the PFC and anterior cingulate have increased
blood oxygenated levels after smoking cannabis (Kanayama et al., 2004). All these
changes in the PFC can have implications for behavioural task performance.
Working memory tasks such as the T-maze and radial arm maze require the
prefrontal cortex to maintain and make decisions based on cues found in the
environment. Systemic injections of THC cause impairments on these working
memory tasks (Jentsch et al., 1997; Lichtman et al., 1996). Low doses of THC
micro-infused into the PFC surprisingly makes an animal more anxiolytic, in
contrast to high doses that produce an anxiogenic effect (Rubino et al., 2008).
Activation of CB1R with low doses of a full agonist can also potentiate the
acquisition of a subthreshold fear memory (Draycott et al., 2014). Combined these
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findings suggest that the PFC is a region susceptible to endocannabinoid
modulation and that unique connections shared with both the vHPC and BLA make
it a region of special interest in the neural circuitry described below.

1.2.4 Cannabinoid modulation of the vHIPP-PFC-BLA circuit

As discussed above, the cannabinoid signaling system, through either
endogenous or exogenous compounds, can substantially alter behaviour and
neuronal functioning separately in the BLA, vHPC, and PFC (Draycott et al., 2014;
Loureiro et al., 2015; Loureiro et al., 2016; Robbe et al., 2006; Tan et al., 2011).
However, each area functions independently and is part of a dynamic system with
recurring connections between these regions. The effects of cannabis, specifically
THC, may alter how each region coordinates with other regions. For instance,
systemic THC decreased functional connectivity between the amygdala and PFC
in humans, during poor performance on the re-appraisal of negative stimuli
compared to controls (Gorka et al., 2015). Oral administration of CBD can also
decrease at rest BOLD signalling in both the amygdala and hippocampus (De
Crippa et al., 2014).

In rodents, systemic THC can alter neuronal activity in the PFC and vHPC
(Aguilar et al. 2016; Robbe et al., 2006). One study found that average firing rates
of single unit neurons in the PFC decreased, whereas no change was found in
cells recorded in the ventral hippocampus (Aguilar et al., 2016). Furthermore, THC
increased coherence between both regions in the Delta frequency band which is
associated with activity at rest. A caveat to this study was that no consideration
between cell types were controlled for during single unit recordings. Therefore, the
combined activity of principal and interneuron populations could have possibly
masked any independent effects under the presence of THC. In the current
literature, no study has yet addressed how THC can alter single unit populations
in both the vHPC and PFC. Furthermore, the combination of THC+CBD has yet to
be explored in the modulation of neural circuit dynamics in the mammalian brain.
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1.3 Research Aims and Hypothesis

The endocannabinoid system is critical for the proper health and
development of the mammalian brain (Meyer, Lee, & Gee, 2018). Mental health
disorders such as schizophrenia have been linked to disruption of the
cannabinoid system in mesolimbic areas of the brain (Laviolette & Grace, 2006).
One pathological manifestation of schizophrenia is persistent thoughts of
hallucinations and delusions. Cannabinoid compounds may modulate the
mesolimbic system and may be partially responsible for inappropriately
reinforcing the distorted emotional significance of everyday events within the
schizophrenic population (Laviolette & Grace, 2006).

To investigate this hypothesis, our research group has tested how THC can
modulate the cannabinoid system within mesolimbic areas of the brain. In the BLA,
PFC, and vHPC, we demonstrate that THC, or the activation of its target receptor,
CB1R, can impair cognition, anxiety, sociability, learning and memory, and rewardrelated behaviours (Ahmad et al., 2016; Draycott et al., 2014; Loureiro et al., 2015;
Loureiro et al., 2016; Renard et al., 2017a, Renard et al., 2017b; Tan et al., 2010,
Tan et al., 2011). Building on this research, we wish to investigate how to prevent
these impairments by countering the effects of THC. As previously discussed, CBD
combined with THC can restore impairments in cognition, attention, sociability,
anxiety and emotional processing (Englund et al., 2012; Fusar-Poli et al., 2009;
Jacobs et al., 2016; Malone et al., 2009; Wright et al., 2013). Therefore, this
phytocannabinoid combination has potential therapeutic benefits in select
behavioural paradigms and neuropsychiatric tests. However, the precise
mechanisms by which CBD may counteract the effects of THC on brain circuits
linked to cannabis-related neuropsychiatric disorders has not yet been clarified.

Our research group has previously demonstrated that cannabinoid
transmission in the BLA can alter pyramidal cell activity in the PFC (Tan et al.,
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2010; Tan et al., 2011). This was done using a full, synthetic CB1R agonist,
WIN55,212-2, as a method to modulate the endocannabinoid system. However,
we have not yet examined how the effects of plant-derived, pure THC (a partial
agonist of the CB1R), may alter neuronal activity states in the PFC. Furthermore,
systemic administration of THC can induce changes in the single unit and local
field measures between the PFC and vHPC (Aguilar et al., 2016). Given the
position of the BLA as a region that projects directly to both areas (Knapska et al.,
2007; Sah et al., 2003), we wanted to explore how THC might impact this circuitry.
Furthermore, CBD can act as a potential therapeutic when combined with THC
and independently it can alter neuronal activity of other regions in the mesolimbic
system such as the NASh (Boggs et al., 2017; Norris et al., 2016). The current
literature has yet to explore whether the combination of THC+CBD can reverse
electrophysiological changes induced by THC.

My overarching hypothesis is that acute exposure to THC in the BLA
is sufficient to cause an overexcitation of both ventral hippocampal and
prefrontal cortex as reflected by increased neuronal and oscillatory activity
states and that co-administration of CBD will prevent this effect.

In this thesis, I have addressed this hypothesis with the following specific
experimental aims:
1) Characterize the effects of intra-BLA THC administration on
single unit and LFP activity in the PFC.

2) Characterize the effects of intra-BLA THC administration on
single unit and LFP activity in the vHPC.

3) Determine if CBD co-administration with THC can block the
effects of THC alone on the PFC-vHPC circuit.
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2. Methods

2.1

Animals and Housing
Adult male Sprague-Dawley rats were obtained from Charles River

(Quebec, Canada) and maintained an average weight of 300-400g on testing day.
Rodents were pair housed in a temperature controlled 12-hour light-dark cycle at
the animal care facility at the University of Western Ontario. Water and food were
given ad libitum and housing conditions consisted of being placed in a plexiglass
box with corn bedding and environmentally enriched objects (chewing wood
blocks, paper towel, and paper nesting material).

2.2

In Vivo Electrophysiology
All methods for preparation of single unit recordings in the PFC and vHPC

follow protocols previously described (Laviolette et al., 2005). All recordings were
performed under urethane anesthesia (1.5/kg, i.p, Sigma-Aldrich) and rodents
were placed in a stereotaxic frame with a heat pad to maintain a body temperature
of 37 degrees Celsius. Scalpel incisions were made on the surface of the head
and holes were drilled in the skull overlying on the targeted structures of the study:
mPFC (AP: +3mm, L+/- 0.8 to +/ 1mm, DV -2.5 to -4.5 mm from the dural surface),
BLA (AP: -3.0mm, L=/- 5.0mm, DV - 7.4mm from dural surface), and vHPC (AP: 5.6, ML: 5, DV:(-6-7.5mm).

Electrodes were pulled from borosilicate glass with an average impedance
of 6 and 8 MΩ and were filled with 2% Pontamine Sky Blue solution (SigmaAldrich). For recordings, extracellular signals were amplified using a MultiClamp
700B amplifier (Molecular Devices) and recorded using a Digidata 1440A
acquisition system (Molecular Devices) with pCLamp 10 software. Two channels
were used (PFC channel 1 and vHPC channel 2) and were sampled to obtain both
single unit recordings (bandpass 0.5 and 3 kHz) and local field potentials (low pass
at 0.3 kHz). Micro electrodes were connected to the channels via a tungsten wire
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and electrodes were slowly inserted to both areas of the brain. Once in, electrodes
were left to rest for fifteen minutes before searching for isolated recordings.
Baseline spontaneous activity was recorded for at least 5 minutes before micro
infusions of drugs into the BLA.

Neuroexplorer (Nex Technologies) was used for LFP, crosscorrelation, and
coherence analysis. Preprocessing consisted of decimating the signal to 1kHz and
low pass filtering (IIR butterworth filter at 100, filter order 3, 0.5 shifts in a 2 s
window. Spectrogram analysis settings pre-processed data with a maximum
frequency of 100, 2048 frequency values, normalized to raw PSD. Oscillations
were segmented based on frequency range: Delta (0.5-4Hz), Theta (4-7Hz), Alpha
(7-14Hz), Beta (14-30Hz), Low Gamma (30-58Hz), and High Gamma (62-80Hz).

Both crosscorrelation and coherence analysis are statistical tests used to
assess the degree of connectivity between multiple regions. In this case, both tests
were used to determine whether LFP signals in the vHPC co-occurred with LFP
signals in the PFC across recording sessions. For the auto-correlation, the vHPC
signal was correlated in reference to the PFC signal and averaged across a fiveminute baseline to produce a single data point. This was repeated to obtain a data
point for a five-minute post-drug infusion period. Both values are represented as a
correlation value, with the highest possible crosscorrelation 1.0 representing both
LFP signals completely overlapping at the same time point. Using a repeated
measures ANOVA, both correlation values are compared between groups to
determine changes in PFC-vHPC LFP signal overlap. The coherence analysis
takes a similar approach but differs in two respects. First, it compares vHPC to
PFC signal overlap as a function of frequency (Delta, Theta, Alpha, Beta, &
Gamma). Thus, data points obtained are restricted to each oscillation range.
Second, more than one data point is obtained with respect to each oscillation range
because this analysis is not restricted to using data at the same time-point. Instead
it looks at overlap across the entire five-minute baseline compared to the entire
five-minute post-infusion period. Therefore, crosscorrelation compares overlap
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between PFC-vHPC at the same time point whereas coherence is only interested
in total signal overlap within each oscillation range.

PFC pyramidal cells were identified based established criteria of firing
frequency (<10 Hz), waveform shape, duration of action potential (> 2.5 ms), and
burst firing. Bursting patterns were identified when a cell fires 3 consecutive spikes
with an inter-spike interval of <45ms. Percentage of burst spike count was
determined by dividing the total bursts by the total amount of spikes in the same
five-minute period. Selection for vHPC principal neurons in the current dataset
were for cells that had baseline firing rates of 0.5-5hz (Goonawardena, Riedel, &
Hampson, 2011). The total sample of animals used in each group are: Vehicle N
= 8, THC N = 9, CBD N = 8, THC+CBD 100ng:100ng N = 10, THC+CBD
100ng:500ng N = 4, CBD 500ng N = 3.
2.3 Drug Preparation
Both THC (Cayman Chemical) and CBD (Tocris) were used in the study.
THC stored in ethanol was dissolved in cremophor and saline (1:1:18). Ethanol
was evaporated from the working solution through evaporation nitrogen gas. CBD
in powder form was dissolved in cremophor and then into saline. Both THC and
CBD mixtures independently and combined consisted of a final concentration of
5% cremophor in the working solution. Drugs were micro infused into the BLA with
a microinjector (Hamilton Syringe 10 ul) at a volume of 0.5 ul slowly over one
minute.

2.4 Histology

Upon completing electrophysiological recordings, rodent brains were
extracted and placed in a 10% formalin solution for at least 24 hours. Then brains
were moved to a formalin-sucrose solution for at least 5 days. Brains were sliced
at 60 µm and mounted on slides. Slides were then stained with neutral red (Sigma
Aldrich) and placements for BLA, vHPC, and PFC were verified using light
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microscopy. Any rodents showing placements outside the boundaries defined by
Paxinos and Watson (2005) were excluded from data analysis.

2.5 Statistical Analyses

Electrophysiological data were analyzed with either a one or two-way
ANOVA where appropriate. Post hoc analyses were performed using Fisher’s LSD
tests.
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3. Results

3.1 Histological Analyses

Analysis of histology revealed the Hamilton syringe placements to be
localized in the anatomical boundaries of the BLA according to the Rat Brain Atlas
(Paxinos & Watson, 1996). Pontamine blue dot and electrode tracks were used to
confirm placements of the last recorded cell in the anatomical boundaries of both
the prelimbic regions of the PFC and vHPC. Figure 1A presents a microphotograph
displaying a representative placement within the PFC. Figure 1B displays a
schematic illustration showing representative PFC placements along the rostralcaudal axis. Figure 1C presents a microphotograph of injector placements in the
BLA. Figure 1D displays a schematic illustration of rostral-caudal placements
within the BLA. Figure 1E is a representative microphotograph of a placement
within the vHPC. Figure 1F displays a schematic illustration of rostral-caudal
placements within the vHPC.
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Figure 1. Histological analysis of BLA injection and PFC & vHPC recording sites. A)
Microphotograph of a presentative PFC recording site. B) Schematic representation of PFC
recording locations. C) Microphotograph of representative BLA injection site. D) Schematic
representation of BLA injector locations. E) Microphotograph of vHPC recording sites. F)
Schematic representation of vHPC recording locations. Symbols: Vehicle, THC 100ng, CBD
100ng,
CBD 500ng, THC+CBD 100ng:100ng, THC+CBD 100ng:500ng.

3.2 The effects of BLA cannabinoid administration on PFC Single Unit
activity

A one-way ANOVA comparing the mean firing rates of single unit activity
revealed THC significantly increased pyramidal cell firing in the PFC. Overall, there
was a significant difference between groups (F(5,95) = 2.453, p = 0.039). Following
this, a Fisher’s LSD post-hoc test comparing groups means revealed that infusion
of THC into the BLA significantly increased pyramidal cell firing compared to
vehicle (p = .008), CBD 100 ng (p = .003), THC+CBD 100ng:100ng (p = .039),
THC+CBD 100ng:500ng (p = .011), and CBD 500 ng (p = .013) infusions. When
CBD was combined with THC at both ratios, this blocked the THC mediated
increase. All other groups that contained CBD showed no increase compared to
vehicle. In addition, a one-way ANOVA comparison on PFC single unit bursting
rate found a significant difference, F(5,95) = 3.458, p = .006, where THC infusions
increased bursting firing compared to all other groups (i.e., Vehicle p = .001, CBD
100 ng p < .001, THC+CBD 100ng:100ng p < .003, THC+CBD 100ng:500ng p =
.004, and CBD 500ng p = .003). Once again, all other groups were no different
compared to vehicle.
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Figure 2. In vivo single unit recording activity in the PFC. A) Representative rastergram showing
firing frequency of PFC pyramidal cell neurons during intra-BLA THC microinfusion. B) Percentage
of cells within each group classified as cells that increase more than 10%, decrease more than
10%, and cells that do not change beyond +/-10%. C) Percentage difference in mean firing rates.
* indicates significantly different from all groups. D) Percentage change in mean bursting rates. *
indicates significantly different from all groups. Sample size: Vehicle (N=17), THC 100ng (N=17),
CBD 100ng (N=20), THC+CBD 100ng:100ng (N=20), THC+CBD 100ng:500ng (N=15), CBD 500ng
(N=12).

3.3 The effects of BLA cannabinoid administration on vHPC Single Unit
activity

Overall, all groups containing CBD decreased ventral hippocampus
principal cell firing. A one-way ANOVA comparing mean firing rates of ventral
hippocampal single unit activity found a significant difference between groups
(F(5,103) = 4.575, p = 0.001). A follow up Fisher’s LSD post-hoc test compared all
groups revealing Vehicle and THC infusions and they were not significantly
different from one another, p = .699. In contrast, Vehicle infusions were
significantly different from all groups that contained CBD: CBD 100ng, p = .015,
THC+CBD 100ng:100ng, p = .007, the THC+CBD 100ng:500ng, p < .001, and
CBD 500ng, p = .002. BLA infusions of THC were also significantly different from
all groups that contained CBD: CBD 100ng, p = .37, THC+CBD 100ng:100ng, p =
.007, THC+CBD 100ng:500ng combination, p = .001, CBD 500ng, p = .007. All
groups containing CBD were not significantly different from one another.
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Figure 3. In vivo single unit recording activity in the vHPC. A) Representative histogram showing
firing frequency of vHPC principal cell neurons during intra-BLA THC+CBD microinfusion. B)
Percentage of cells within each group classified as cells that increase more than 10%, decrease
more than 10%, and those that have neither directional change within 10%. C) Percentage
difference in mean firing rates. * indicates significantly different from vehicle and THC. Sample size:
Vehicle (N=14), THC 100ng (N=15), CBD 100ng (N=20), THC+CBD 100ng:100ng (N=27),
THC+CBD 100ng:500ng (N=18), CBD 500ng (N=15).

3.4 The effects of BLA cannabinoid administration on PFC LFP activity

Given significant differences at the single unit level, we then analysed data
at the local field potential level. This analysis involved comparing all six groups
across six oscillation ranges (Delta, Theta, Alpha, Beta, Low Gamma, and High
Gamma). Overall, THC caused an increase in power for low and high Gamma. For
low Gamma (i.e., 62HZ-80HZ), a one-way ANOVA found a significant difference,
F(5, 85) = 2.442, p = .041 across groups where both THC 100ng and THC+CBD
100ng:100ng were significantly different from Vehicle (p= .037; p = .038) and CBD
100ng (p= .011; p = .010). For High Gamma, a one-way ANOVA found a significant
difference, F(5, 85) = 3.524, p =.006 across groups where only THC significantly
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increased power post-infusion compared to all other groups (i.e., Vehicle p = .002;
CBD 100ng p= .001, THC+CBD 100ng:100ng p = .001, THC+CBD 100ng:500ng
p= .002, CBD 500ng p= .003). One-way ANOVA analysis revealed no significant
differences between groups across Delta (F(5, 85) = 1.697, p = .144), Theta (F(5,
85) = .652, p = .661), Alpha (F(5, 85) = .855, p = .515), and Beta (F(5, 85) = 1.201,
p = .316).
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Figure 4. Local Field Potential recordings in the PFC. A) Diagram of a representative cell’s LFP
total power across 0-100 HZ oscillation range. Orange is total power across five minutes after
infusion of THC. B) Spectrogram depicting change in power in the high gamma oscillation (62-80
Hz). C) Change in LFP averaged across groups in low gamma range. * indicates significantly
different from vehicle and CBD 100ng. D) Change in LFP average across groups in high gamma
range. * indicates significantly different compared to all groups. Sample Size: Vehicle (N=16), THC
100ng (N=16), CBD 100ng (N=20), THC+CBD 100ng:100ng (N=20), THC+CBD 100ng:500ng
(N=15), CBD 500ng (N=12).

3.5 The effects of BLA cannabinoid administration on vHPC LFP activity
This next section compared LFP difference in the vHPC. A one-way ANOVA
analysis revealed no significant difference between groups across Delta (F(5, 88)
= .486, p = .786)), Theta (F(5, 88) = 1.946, p = .095)), Alpha (F(5, 88) = 1.167, p =
.332), Beta (F(5, 88) = .424, p = .831)), Low Gamma (F(5, 88) = .929, p = .466)),
and High Gamma (F(5, 88) = .174, p = .972)) oscillations. Therefore, THC had no
single unit effect and no change in LFP in the ventral hippocampus. CBD, in
comparison to single unit recordings, did not alter LFPs in the ventral
hippocampus.

34

vHPC Low Gamma (30-58 Hz)

5A
Change in total power (Difference of drug from baseline)

0.02

0.015

0.01

0.005

0

-0.005

-0.01

-0.015
Vehicle

THC 100ng

CBD 100ng

THC+CBD
100ng:100ng

THC+CBD
100ng:500ng

CBD 500ng

THC+CBD
100ng:500ng

CBD 500ng

vHPC high Gamma (62 - 80Hz)

5B
Change in total power (Difference of drug from
baseline)

0.14

0.12

0.1

0.08

0.06

0.04

0.02

0
Vehicle

THC 100ng

CBD 100ng

THC+CBD
100ng:100ng

35

Figure 5. Local Field Potential recordings in the vHPC. A) Change in LFP averaged across groups
in low gamma range. B) Change in LFP averaged across groups in high gamma range. Sample
size: Vehicle (N=16), THC 100ng (N=16), CBD 100ng (N=20), THC+CBD 100ng:100ng (N=20),
THC+CBD 100ng:500ng (N=15), CBD 500ng (N=12).

3.6 Crosscorrelation Analysis between PFC and vHPC

After analyzing the local field potential within a region, we decided to
compare changes between regions. This analysis looks at whether THC or CBD
alters crosscorrelations or coherence levels between the PFC and vHPC. A twoway repeated measures ANOVA revealed no overall main effect between preinfusion and post infusion times, F(1, 129) = .550, p = .460. In addition, no withinsubjects interaction between groups and infusion time were revealed in the data
set, F(5,129) = .099, p = .992.
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Figure 6. PFC-vHPC Crosscorrelation. A) Correlogram of Crosscorrelation scores between PFC
and vHPC connectivity. Sample size: Vehicle (N=20), THC 100ng (N=21), CBD 100ng (N=33),
THC+CBD 100ng:100ng (N=23), THC+CBD 100ng:500ng (N=21), CBD 500ng (N=17).
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3.7 Coherence Analysis between PFC and vHPC

For our final analysis, we divided the data within each oscillation range and
compared between PFC-vHPC activity using a coherence analysis. Overall, there
was no significant difference in a two-way ANOVA across all oscillation ranges.
Time is listed as the variable between pre- and post-infusion. Overall, the analysis
revealed no significant main effect for Delta time (F(1,127) = 1.649, p = .201)) or
interaction TimexGroup (F(5,127) = .760, p = .580)); Theta Time (F(1,127) = .232,
p = .631)) or interaction TimexGroup (F(5,127) = 1.030, p = .403)); Alpha Time
(F(1,127) = .591, p = .002)) or interaction Alpha TimexGroup (F(5,127) = .061, p
= .079)); Beta Time (F(1,127) = .010, p = .921)) or interaction TimexGroup
(F(5,127) = .492, p = .781)); Low Gamma Time (F(1,127) = .025, p = .875)) or
interaction TimexGroup (F(5,127) = .272, p = .927)); High Gamma Time (F(1,127)
= .097, p = .756)) or interaction TimexGroup (F(5,127) = .299, p = .913)).
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Figure 7. Coherence analysis between PFC-vHPC activity A) Delta coherence. B) Theta
coherence. C) Alpha coherence. D) Beta coherence. E) Low gamma coherence. F) High gamma
coherence. Sample size: Vehicle (N=20), THC 100ng (N=21), CBD 100ng (N=33), THC+CBD
100ng:100ng (N=21), THC+CBD 100ng:500ng (N=21), CBD 500ng (N=17).
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4. Discussion

4.1 PFC single unit activity is altered by THC but prevented by coadministration of CBD

Previous findings from this research group have already demonstrated that
a full agonist for the CB1R in the BLA can alter the single unit activity of neurons
in the PFC (Tan et al. 2010; Tan et al., 2011). Given these findings, we performed
a series of in vivo single unit recordings in both the PFC and vHPC and
investigated the effects of the partial CB1R agonist THC in the BLA. Our analyses
revealed that micro-infusions of THC caused an increase in pyramidal cell firing
and bursting rates in the PFC.

The majority of CB1R expression in the BLA is located on interneuron
populations

(Marsicano

&

Lutz,

1999).

Furthermore,

application

of

endocannabinoid agonists on BLA interneurons reduces spontaneous evoked
activity, which can potentially reduce overall inhibition on BLA pyramidal cell firing
(Howlett et al., 1986; Sullivan 1999; Hoffman & Lupica, 2000; Wilson & Nicoll,
2001; Kano et al., 2009). Given these findings, along with the present results, our
proposed model suggests that THC increases activation of BLA pyramidal cell
projections to increase spontaneous single unit activity in the PFC. Our lab has
already shown that activation of BLA CB1R can potentiate non-salient stimuli
during the acquisition of an emotional memory and create a conditioned place
aversion of a morphine reward memory (Tan et al., 2010; Tan et al., 2011). As
THC is a partial agonist of the CB1R, it is possible that micro-infusions into the
BLA could also potentiate non-salient stimuli during emotional memory acquisition.
Although we have not tested this in the BLA, THC micro-infusions into the NASh
can potentiate the acquisition of a fear memory at sub-threshold levels of foot
shock (Fitoussi et al., 2018). Given the well-known psychotropic effects associated
with THC, it is possible that increasing activity of the BLA to alter PFC activity leads
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to misattributing the salience of normal objects in the environment, a behaviour
that is commonly found in psychosis and schizophrenia (Laviolette & Grace, 2006).

Next, we investigated whether the combination of THC with CBD at a ratio
of 1:1 and 1:5 would block the effects of THC. In both cases, micro-infusions of the
combination prevented PFC pyramidal cell increases as seen with THC. In
addition, CBD at 100 and 500ng did not alter PFC activity compared to vehicle.
While there yet exists a clear mechanism to explain how CBD can reverse the
effects of THC, a number of studies have demonstrated the potential therapeutic
advantage of the formulated dose. In rodents, systemic combinations of 1:1 or 1:3
can prevent THC induced conditioned place aversion or deficits associated with
social interaction (Vann et al., 2008; Malone et al., 2009). In humans, a 1:2 oral
dose can prevent impairments in affect recognition induced by THC (Hindocha et
al., 2015). Current research has yet to investigate how the combined dose can
interact in specific regions of the brain. The current findings are the first to
demonstrate that a combined THC+CBD formulation blocks electrophysiological
changes induced by THC in the brain.
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8A

Figure 8A. Proposed model of BLA cannabinoid transmission on PFC activity. THC into the BLA
binds to CB1Rs that are primarily located on GABA interneuron populations. Activating these
receptors inhibits neurotransmitter release on terminals, therefore causing an overall dis-inhibition
of BLA pyramidal cell activity. Increases in BLA activity are associated with changes to PFC
pyramidal cell targets, which are associate with increases in single unit firing, bursting, and LFPs
for high frequency gamma. The THC+CBD formulation is sufficient to prevent these effects. The
mechanism for how these two compounds interacts is still not clear.

4.2 Cannabidiol decreases single unit activity in the vHPC

In the vHPC, THC micro-infusions did not alter single unit pyramidal cell
activity compared to vehicle. Previous findings have demonstrated systemic THC
infusions show no change in pyramidal cell firing (Aguilar et al., 2016). It is possible
that the dose used in the current study was not high enough to induce an
electrophysiological change in the vHPC, as a higher dose of BLA THC infusions
(1ug) have been associated with anxiolytic effects (Rubino et al., 2008). In contrast
to results in the PFC, CBD micro-infused in the BLA caused a decrease in vHPC
single unit activity. Surprisingly, this effect was still present when CBD was
combined with THC.
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Interestingly, intracranial infusions of CBD into the NASh, at this same dose,
have previously been shown to attenuate single unit activity of dopamine neurons
in the VTA (Norris et al., 2016; Renard et al., 2016). The application of a 5HT-1A
antagonist while co-administered with CBD was sufficient to prevent this effect,
supporting the 5HT-1A serotonin receptor as one of its main sites of action (Norris
et al., 2016; Russo et al., 2005). Activation of the 5HT-1A receptor can cause the
inhibition of postsynaptic action potentials, therefore decreasing the cell’s firing
output (Polter & Li, 2010; Tada et al., 2004). With the current project’s findings, our
proposed model suggests that CBD, via activation of the 5HT-1A receptors on BLA
pyramidal cells, inhibits principal cell firing rates in the vHPC. Using patch-clamp
recordings, researchers have demonstrated that inactivating BLA projections to
vHPC pyramidal cells causes decreased cell firing because of a decrease in
glutamate release (Felix-Ortiz et al., 2013). It is possible that CBD inhibits output
of BLA pyramidal cell activity to the vHPC by decreasing glutamate release.
Inactivating these pathways is related to social and anxiety-related behaviour
changes (Felix-Ortiz et al., 2013; Felix-Ortiz & Tye, 2014). Further research should
investigate whether CBD in the BLA is sufficient to alter similar behaviours through
inactivating projections to the vHPC.

9A
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Figure 9A. Proposed model of BLA cannabinoid transmission on vHPC activity. CBD infused into
the BLA binds to 5-HT1A receptors located on the soma and dendrites of pyramidal cells. Activating
these receptors is associated with reduced EPSP generation to reduce overall action potential
firing. This causes a decrease in pyramidal output to vHPC principal neurons, therefore reducing
the overall activity of these cells. Surprisingly, the combination with THC is insufficient to prevent
this effect, indicating this pathway’s potential preference for CBD. Independent of CBD, THC within
the BLA does not increase vHPC single unit or LFP activity.

4.3 Cannabinoid transmission alters cortical LFP activity

In contrast to cell-specific firing rates, we next investigated measures of
indirect changes in cell input with LFPs. Analysis across oscillation ranges
revealed that BLA THC caused an increase in power for gamma oscillations, with
the strongest effect seen at the higher frequency (62-80Hz). Furthermore, the
combination with CBD prevented this effect and returned post-infusion power
changes similar to vehicle. The application of BLA CBD did not alter LFP signals
compared to vehicle. In the vHPC neither THC, CBD, nor the combination led to
changes in any oscillation patterns.

Coordination of cortical gamma oscillations integrate brain functions
associated with cognitive and sensory processing (Basar et al., 2001).
Disturbances in this network can potentially make the brain vulnerable to
behavioural abnormalities. Network gamma oscillations in rodents are altered by
activation of the CB1R, leading to alterations in impairments of cognitive and
sensory processes (Hajos, Hoffmann, & Kocsis, 2008). As well, systemic
application of THC in both adolescent and adult rodents have previously been
shown to alter power for high frequency oscillations (Renard, 2017a; Robbe et al,
2006).

One neuropathological feature of schizophrenia is the disturbance of PFC
gamma oscillations, leading to increased hallucinations and deficits in cognitive
processes (Lee et al., 2010; Symond et al., 2005). In healthy subjects, acute THC
administration has been associated with increase gamma activity and is correlated
with increases in symptoms associated with psychosis (Nottage et al., 2015).
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Therefore, THC’s negative effects can potentially act through alterations in the
gamma oscillation range. We demonstrate that a combination of CBD may act to
prevent these disturbances, as the literature suggests a therapeutic benefit of
higher CBD to THC ratios (Boggs et al., 2017).

4.4 BLA cannabinoid transmission does not alter PFC-vHPC connectivity.

For the final set of data, we performed an exploratory analysis investigating
PFC-vHPC connectivity across both general activity (Crosscorrelation) and within
oscillations (Coherence). The crosscorrelation takes the average shape of the LFP
signal within a five-minute baseline period. The average shape within the vHPC is
applied on top of the average shape of the PFC LFP signal. The degree of overlap
on both signals is then assigned a correlation value, with the highest
crosscorrelation 1.0 meaning the signals completely overlap. Coherence is a
similar method, but it looks at comparing the degree of vHPC to PFC signal overlap
as a function of frequency (Delta, Theta, Alpha, Beta, & Gamma). In both
crosscorrelation and coherence analysis, post-infusion values are compared
against baseline values to determine if any significant differences exist between
treatment groups.

In both data sets, micro-infusions of THC, CBD, or the combination in the
BLA did not cause any significant differences. Our findings are consistent with
previous research that showed systemic THC does not alter Theta or Gamma
oscillations, although researchers show increased Delta coherence in awake
animals (Aguilar et al., 2016). Our findings suggest that while cannabinoid
transmission in the BLA is sufficient to alter single-unit and LFP activity, it does not
alter the coordination between brain regions. Future studies should explore
whether a higher dose of THC or the application of a full CB1R agonist can change
the coordinated activity between regions.
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4.5 Implications

The current thesis adds to the literature on cannabinoid transmission within
the mesolimbic system. Specifically, this is the first study to demonstrate that a
combination of THC+CBD is enough to negate the effects of THC on
electrophysiological activity of mesolimbic brain areas. Within regions of the BLA,
PFC, and vHPC, our research group has demonstrated that THC or the activation
of its target receptor, CB1R, can impair cognition, anxiety, sociability, learning and
memory, and reward-related behaviours (Ahmad et al., 2016; Draycott et al., 2014;
Loureiro et al., 2015; Loureiro et al., 2016; Renard et al., 2017a; Renard et al.,
2017b; Tan et al., 2010, Tan et al., 2011). Current literature suggests the
combination of THC and CBD can reverse some of these impairments, although
the exact mechanism is still not understood (Boggs et al., 2018).

The model presented in Figures 8 and 9 can potentially explain these
effects. Activation of CB1R in the BLA increases the activity of PFC pyramidal
cells, which can potentiate the processing of emotionally neutral stimuli (Tan et al.,
2010; Tan et al., 2011). Furthermore, increased activity of cortical gamma
oscillations can impair cognition and produce acute deficits, as seen in
schizophrenia (Lee et al., 2010, Nottage et al., 2015; Renard et al., 2017a; Symond
et al., 2005). In our current study, the combination of THC+CBD in the BLA blocked
this overexcitation of PFC activity. Overexcitation of the vHPC has also been
implicated in modulating the mesolimbic system to produce schizophrenic-like
deficits (Grace et al., 2010). Although we were surprised to find THC did not
increased activity in this region, CBD with or without THC decreased overall
principal neuron activity in the vHPC. These findings are supported in healthy
human populations, in which oral administration of CBD decreases resting state
activity within the amygdala and ventral hippocampus (De Crippa et al., 2004).
Given how CBD interacts with the 5HT-1A receptor, decreased BLA pyramidal cell
firing is responsible for inducing a decrease in vHPC activity. Our findings provide
a novel avenue for investigating the anti-psychotic-like benefits of CBD because
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of its ability to alter the vHPC. Modulating the mesolimbic system through
cannabinoid transmission may partially be responsible for inappropriately
reinforcing the distorted emotional significance of everyday events within the
schizophrenic population (Laviolette & Grace, 2006). The combined use of
THC+CBD can potentially mitigate this impact on the mesolimbic system by
simultaneously preventing overexcitation of cortical and hippocampal activity.

5. Limitations

Although our findings demonstrate a clear relationship between BLA
cannabinoid transmission and its effects on the PFC and vHPC, more experiments
are needed to better characterize this circuitry. In particular, we could not
demonstrate whether cells recorded in either region were directly or indirectly
affected by afferent projections from the BLA. For instance, BLA projections not
only synapse on pyramidal cell populations but also on GABAergic interneuron
populations. Associated changes in either region in this study could be mediated
by altering activity in interneuron populations. Increase of cortical GAMMA
oscillations are mediated in part by dysregulation of local interneuron populations
(Buzsaki & Wang, 2012). A follow-up project should investigate whether the effects
seen with infusions made into the BLA directly interfere with the PFC or vHPC or
are mediated from a different cell. One method to determine this is orthodromic
validation. This would require recording in the BLA to PFC or vHPC innervation
before drug infusion. In this paradigm, experimenters would stimulate neurons in
PFC or vHPC target regions, which would conduct back up the axon of a BLA
pyramidal cell. When co-stimulation of BLA and target structures negate the other
area’s conduction, the recorded cell is interpreted as a direct projection.
Furthermore, recordings of interneuron populations within the vHPC or PFC would
indirectly provide detail as to whether THC or CBD may have an indirect effect. In
the case of VTA dopamine neurons, previous research has demonstrated changes
via nucleus accumbens CBD infusions to be mediated by changes in VTA
interneuron activity (Norris et al., 2016).
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In the present study, THC did not cause a change in vHPC recorded
neurons. One limitation to this interpretation was that we only used one dose of
THC. In the case of CBD, two doses were used to confirm its effects. It is possible
that a higher dose of THC can still cause a change in vHPC activity, given how
previous studies have used BLA infusions of 1ug and above (Rubino et al., 2008).
Despite this, our dose was still sufficient to elicit a change in PFC activity. Followup research should include a low THC dose (10 ng) that has not elicited any
behavioural or electrophysiological changes in rodents (Norris et al., 2016). By
adding a lower dose, future research can determine the lower bound of BLA THC
infusions that cause electrophysiological changes.

Future Directions

We demonstrated the reversal effects of a combined THC+CBD
formulation, however we have yet to demonstrate the underlying mechanism
behind this. Although CBD has opposite effects on the CB1R compared to THC,
CBD’s overall low affinity for this receptor suggests that its main site of action is
dependent on a different receptor (Pertwee, 2004). In this case, we could not
determine which receptor type is responsible for the decreases found in the ventral
hippocampus. Given the pharmacological binding profile of CBD, potential target
receptors are 5-HT1A, D2, Mu opioid, or GPR55 (Kathmann et al., 2016; Russo et
al., 2005; Ryberg et al., 2007; Seeman, 2016). Previous research has already
indicated that blockade of the 5-HT1A receptor prevents the effects of systemic
and local CBD on emotional memory acquisition and changes in mesolimbic
neuron firing (Katsidoni et al., 2009; Norris et al., 2016). Future research should
combine CBD with a 5-HT1A antagonist to determine if CBD’s main site of action
in the BLA is mediated by the serotonin receptor.

Beyond electrophysiology, future studies should explore the independent
and combined behavioural effects of THC and CBD. Activating BLA CB1R and
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increasing PFC activity can potentiate non-emotionally salient stimuli to be
encoded in a fear memory (Tan et al., 2010). In fear memory formation, CBD
infused into the shell of the nucleus accumbens alone is sufficient to block
acquisition (Norris et al., 2016). It is possible that the combination of THC+CBD
can prevent potentiation of fear memory and can negate changes in cortical
activity.
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Conclusions

Within the mammalian brain, the proper encoding of environmental stimuli
is regulated by the cannabinoid system. Disruption of this system through cannabis
can lead to either positive or negative effects, depending on the relative ratio of
THC to CBD within the plant. Impaired cognition, anxiety, learning, and memory
are associated with activation of the CB1R via THC in the BLA, vHPC, and PFC.
Combining CBD with THC appears to prevent these acute impairments and could
allow a user to avoid some of the negative effects associated with high amounts
of THC. To test this question, we used in vivo electrophysiology to determine if
THC+CBD can negate THC-induced overexcitation of PFC pyramidal cells. Not
only was the combination effective, it simultaneously decreased ventral
hippocampal activity, possibly another benefit to counter the effects of high THC.
We demonstrate for the first time that THC+CBD has therapeutic benefits that are
demonstrated through neuronal activity in mesolimbic areas of the brain.
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